Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Change in Receivables (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Change in Receivables for 3 consecutive years, with -$464000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Change in Receivables rose 89.83% to -$464000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$464000.0, a 91.48% increase, with the full-year FY2024 number at -$1.3 million, up 75.8% from a year prior.
  • Change in Receivables was -$464000.0 for Q4 2024 at Werewolf Therapeutics, down from -$81000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.6 million in Q4 2022 to a low of -$4.6 million in Q4 2023.
  • A 3-year average of $0.0 and a median of -$230000.0 in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 273.55% in 2023, then skyrocketed 92.03% in 2024.
  • Werewolf Therapeutics' Change in Receivables stood at $2.6 million in 2022, then crashed by 273.55% to -$4.6 million in 2023, then skyrocketed by 89.83% to -$464000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Change in Receivables are -$464000.0 (Q4 2024), -$81000.0 (Q3 2024), and -$230000.0 (Q2 2024).